🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join our friends Brian Rini, MD 🇺🇸and Tom Powles 🇬🇧 (The Uromigos ) as they discuss: ADC 💊DEVELOPMENT IN #BladderCancer PART 1⃣-DRUGS IN REFRACTORY BLADDER CANCER THIS IS PART ONE IN A TWO PART SERIES‼️ GU Sumanta K. Pal, MD, FASCO Cristiane D Bergerot Daniel Heng Andrea Apolo, M.D. Toni Choueiri, MD

Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies dlvr.it/TK8ss6

Chuck and AliciaのPodcast番組「The Good News About Cancer」の紹介。患者さんや研究者へのインタビューをもとにした番組とのこと。彼らの温かい人柄が現れた番組みたいです。 open.spotify.com/episode/3A6FnJ…

open.spotify.com/show/7KtVaRYK3…

The impact of androgen receptor pathway inhibitors as starting treatment in metastatic castration-sensitive prostate cancer on patient outcomes (OASIS Japan) nature.com/articles/s4159… This large retrospective cohort study using Japanese claims data assessed clinical outcomes

デンマーク🇩🇰で実施された新鮮組織検体を使用したWGS, WESの結果 (n=2147)。 1866人（87%)でゲノム情報取得。そのうち1062人 (57%)で少なくとも１つのactionable target geneあり、そのうち256人（24%)が標的治療を受けた。 Annals of Oncology bit.ly/42nlzRB

論文にも書いてありますが、そもそもClavien-Dindo III以上の合併症が少ない手術です。RAPNはOPNと比較して手術時間と温阻血時間が長かったが、入院期間が短く回復が早く、オピオイド使用量が少なく、疼痛が軽度、QOLがよかったとあります。であれば、RAPNの圧勝でしょう。

Listen to "Episode 407: Uromigos Japan - European Delphi Study of mRCCについてdiscussion" by The Uromigos creators.spotify.com/pod/show/the-u…

BOND-003: The final analysis of Intravesical Cretostimogene Grenadenorepvec (n=112). for High-Risk BCG unresponsive NMIBC with CIS. CR=75% & 12 months DFS= 50% (of ITT population). This looks in line with other adenoviral gene therapies - INFa (adstiladein) #AUA25

Little data is available for BCG-unresponsive papillary only NMIBC. Here 52 patients received TAR200 (slow release GEM). 6 month DFS =85% (median follow up 12 mnths). Only 6% needed cystectomy. Well tolerated. Modest numbers/ follow up. More supportive TAR200 NMIBC data #AUA25

Here is a podcast with Neal Shore around the CREST RIII untreated NMIBC BCG +/- PD1 trial which show and EFS advantage but with expected immune related toxicity. Here we discuss the highlights and risk benefit ratio. podcasts.apple.com/gb/podcast/the… #AUA25

The BCG strain should have been specified in the protocol as one of them.

⚡️ In Nature Reviews Urology - Circulating tumour DNA and circulating tumour cells in bladder cancer — from discovery to clinical implementation #BladderCancer Matt Galsky Tom Powles Lars Dyrskjøt nature.com/articles/s4158…

1/2 Here’s our updated advanced urothelial cancer Uromigos Score (20 experts from around the world). It’s designed to give clinical strength/granularity to guidlines (which often give a list of equal options). Thanks to those that took part (on the 2nd slide). As things change,

2/2 Thanks to the team

POTOMAC trial- Durvalumab + BCG shows positive results for DFS in high-risk NMIBC vs BCG alone. sasanlimab (CREST) also had an EFS advantage here: HR 0.68. Consistent results in early disease is compelling. IO tox is relevant in risk/benefit ratio. astrazeneca.com/media-centre/p…

Great news. I want to know more details ASAP. astrazeneca.com/media-centre/p…

1/2 POTOMAC is the last of the 15 PD(L)1 monotherapy IO R3 trials over 10yrs & >8000 pts in bladder cancer. The summary shows 1)clearer activity in earlier disease 2)the biomaker failing 3)PD-L1 & PD1 targeting having equal success 4)An unidentified subset respond in all settings

Love the #ASCO25 Uromigos GU cancers preview and the usual fun banter between Tom Powles Brian Rini, MD silke gillessen Looking forward to an exciting ASCO with a lot of interesting abstracts across GU cancers. Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO Petros Grivas Tres Uramigas ウロミーゴズ

Renal cancer #ASCO25 1) Casdatifan/carbo phase 2 data (RR=41%) ⏩️ R3 PEAK1 2)Biomarkers from sequential tissue from adjuvant atezo study IM010 3) CAR-T (CD70) data cRR20% 4) Final analysis for ipi/nivo ITT (HR 0.71) 5) predicting response to Cabo/nivo from TME & Microbiome